DEFINED DAILY DOSES IN RELATION TO HYPOLIPEMIC EFFICACY OF LOVASTATIN, PRAVASTATIN, AND SIMVASTATIN

被引：82
|
作者：
ILLINGWORTH, DR
ERKELENS, DW
KELLER, U
THOMPSON, GR
TIKKANEN, MJ
机构：
[1] UNIV UTRECHT HOSP, DEPT ENDOCRINOL, UTRECHT, NETHERLANDS
[2] KANTONSSPITAL, DEPT INTERNAL MED, CH-4031 BASEL, SWITZERLAND
[3] HAMMERSMITH HOSP, MRC, LIPOPROT TEAM, LONDON W12 0HS, ENGLAND
[4] UNIV HELSINKI HOSP, DEPT INTERNAL MED, HELSINKI, FINLAND
来源：
LANCET | 1994年 / 343卷 / 8912期
关键词：
D O I：
10.1016/S0140-6736(94)92945-9
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
[No abstract available]
引用
收藏
页码：1554 / 1555
页数：2
相关论文
共 50 条
  • [41] Efficacy of atorvastatin in patients with severe familiar hypercholesterolemia treated with pravastatin, fluvastatin and simvastatin
    Fornengo, P
    D'Affuso, S
    Bruno, A
    Pagano, G
    ATHEROSCLEROSIS, 1999, 144 : 190 - 190
  • [42] COMPARATIVE-STUDY OF THE EFFICACY AND TOLERABILITY OF SIMVASTATIN AND PRAVASTATIN IN PATIENTS WITH PRIMARY HYPERCHOLESTEROLEMIA
    DOUSTEBLAZY, P
    RIBEIRO, VG
    SEED, M
    BERTHEZENE, F
    DEVULDER, B
    FARNIER, M
    GANCEL, A
    GAUTIER, D
    DEGENNES, JL
    HESPEL, JP
    LATAPIE, JL
    REMY, JM
    ROGER, P
    TATER, D
    THOMAS, M
    AVILA, J
    SILVA, PSE
    GONCALVES, FR
    VANHAFE, P
    SIMOES, L
    HUGHES, E
    RYLANCE, P
    WRAY, R
    WILKINSON, P
    DRUG INVESTIGATION, 1993, 6 (06): : 353 - 361
  • [43] A comparative study of the efficacy and safety of atorvastatin, pravastatin, lovastatin and gemfibrozil in the treatment of hyperlipidemic patients
    Hatzitolios, AI
    Delivoria, CF
    Archaniotaki, ME
    Savopoulos, CG
    Kounanis, AD
    Kallinikidis, TG
    Ziakas, AG
    Benis, AD
    ATHEROSCLEROSIS: RISK FACTORS, DIAGNOSIS, AND TREATMENT, 2002, : 313 - 315
  • [44] Fluoroquinolones: Utilisation and Compliance with WHO Defined Daily Doses
    Alisha, Mohd Alfam Shamin Ashraf
    Khan, Abdullah
    Tan, Ching Siang
    Menon, Shashidharan
    Kaur, Jaasminerjiit
    Kalusalingam, Anandarajagopal
    Loy, Mei Jun
    Manan, Mohamed Mansor
    Ming, Long Chiau
    JOURNAL OF YOUNG PHARMACISTS, 2021, 13 (02) : 136 - 142
  • [45] Defined daily doses: a high antibioptic prescription rate?
    Simo Minana, Juan
    ATENCION PRIMARIA, 2011, 43 (12): : 678 - 679
  • [46] HMG COA REDUCTASE INHIBITORS AS LIPID-LOWERING AGENTS - 5 YEARS EXPERIENCE WITH LOVASTATIN AND AN APPRAISAL OF SIMVASTATIN AND PRAVASTATIN
    MAHER, VMG
    THOMPSON, GR
    QUARTERLY JOURNAL OF MEDICINE, 1990, 74 (274): : 165 - 175
  • [47] TREATMENT OF PRIMARY HYPERCHOLESTEROLEMIA - SHORT-TERM EFFICACY AND SAFETY OF INCREASING DOSES OF SIMVASTATIN AND PRAVASTATIN - A DOUBLE-BLIND COMPARATIVE-STUDY
    STALENHOEF, AFH
    LANSBERG, PJ
    KROON, AA
    KORTMANN, B
    DEHAAN, AFJ
    STUYT, PMJ
    KASTELEIN, JJP
    JOURNAL OF INTERNAL MEDICINE, 1993, 234 (01) : 77 - 82
  • [48] SIMVASTATIN AND PRAVASTATIN - A DAILY DOSE OF 40 MG IN THE LONG-TERM TREATMENT OF PRIMARY HYPERCHOLESTEROLEMIA
    STEFANUTTI, C
    VIVENZIO, A
    LUCANI, G
    DIGIACOMO, S
    COLOMBO, C
    BIANCHI, MA
    RICCI, G
    CURRENT THERAPEUTIC RESEARCH-CLINICAL AND EXPERIMENTAL, 1994, 55 (04): : 446 - 454
  • [49] COMPARISON OF PRESCRIBED DAILY DOSES (PDD) WITH DEFINED DAILY DOSES (DDD) FOR SOME ANTIBIOTICS IN 18 ITALIAN HOSPITALS
    SCROCCARO, G
    MARINI, P
    OLIVATO, R
    MARTINI, N
    PROGRESS IN CLINICAL PHARMACY: RATIONAL USE OF DRUGS, 1989, : 228 - 229
  • [50] The hidden magnitude of polypharmacy: using defined daily doses and maximum licensed daily doses to measure antipsychotic load
    My Linh Nguyen
    Sunderland, Bruce
    Lim, Stephen
    Hattingh, Laetitia
    Chalmers, Leanne
    INTERNATIONAL JOURNAL OF CLINICAL PHARMACY, 2019, 41 (06) : 1642 - 1651
12345